Cargando…
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse event...
Autores principales: | Elmaleh, David R., Farlow, Martin R., Conti, Peter S., Tompkins, Ronald G., Kundakovic, Ljiljana, Tanzi, Rudolph E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839593/ https://www.ncbi.nlm.nih.gov/pubmed/31476157 http://dx.doi.org/10.3233/JAD-190507 |
Ejemplares similares
-
Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
por: Zhang, Can, et al.
Publicado: (2018) -
Decoding Alzheimer’s in the age of genome-wide analyses
por: Tanzi, Rudolph E
Publicado: (2013) -
Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?
por: Farlow, Martin R
Publicado: (2010) -
The role of innate immune genes in Alzheimer's disease
por: Griciuc, Ana, et al.
Publicado: (2021) -
A current view of Alzheimer's disease
por: Hooli, Basavaraj V, et al.
Publicado: (2009)